Publication Cover
Synthetic Communications
An International Journal for Rapid Communication of Synthetic Organic Chemistry
Volume 48, 2018 - Issue 19
110
Views
0
CrossRef citations to date
0
Altmetric
Articles

Design and synthesis of novel enantiomerically enriched morpholino [4, 3–a] benzimidazole derivatives as potential bioactive agents

, &
Pages 2575-2583 | Received 06 Jun 2018, Published online: 10 Oct 2018
 

Abstract

A series of chiral morpholino [4, 3-a] benzimidazole derivatives were synthesized effectively from (S)-(-)-2-(α-hydroxyethyl)-benzimidazole and phenacyl bromide derivatives using an efficient synthetic protocol in good yields and moderate diastereoselectivities. The substrate controlled diastereoselective route makes available structurally attractive morpholine-fused benzimidazole derivatives with two chiral centers in enantiomerically enriched forms. The preliminary biological evaluation shows scope for potential applications.

Graphical Abstract

Acknowledgments

PKT is thankful to UGC-BSR, New Delhi for the JRF and SRF awards. Authors express sincere thanks to Dr. Dhanji P. Rajani, Microcare Laboratory, Surat, for availing the antimicrobial screening facilities for the compounds herein.

Supplementary data

Supplemental data (full experimental detail, 1H and 13C NMR spectra, Mass spectra, and HPLC analyses) can be accessed on the publisher’s website.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.